Journal
CANCER CELL
Volume 15, Issue 5, Pages 359-361Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2009.04.005
Keywords
-
Categories
Funding
- NCI NIH HHS [R01 CA107263] Funding Source: Medline
Ask authors/readers for more resources
A recent study published in Nature Medicine reports that low-dose treatment with RGD-mimetic integrin inhibitors may paradoxically enhance angiogenesis and tumor growth. This work implies that delivery of these agents should be redesigned in order to avoid nanomolar plasma concentrations and to improve their efficacy to treat human cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
